Nilotinib Pharos (Nilotinib)

Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling pathways that promote proliferation and survival of leukemic cells, leading to apoptosis of the malignant clone while sparing most normal cells.

The exact dose of nilotinib is determined by the prescribing physician based on the patient’s disease phase, prior therapy, and individual health factors. Dosage adjustments may be required for drug interactions, organ function, or adverse events, and should always follow the prescriber’s written order.

Nilotinib is contraindicated in pregnancy and breastfeeding because it can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while taking nilotinib.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nilotinib belongs to the second‑generation tyrosine‑kinase inhibitor class and offers higher potency against BCR‑ABL compared with first‑generation agents such as imatinib. It is often chosen for patients who need deeper molecular responses or who have resistance/intolerance to earlier TKIs, though safety profiles and drug‑interaction potentials differ.

Nilotinib Pharos should be stored at temperatures below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, heat, and direct sunlight. Do not refrigerate or freeze the product, as this may affect tablet integrity.

Nilotinib Pharos is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). The tablets should be swallowed whole with a glass of water; they must not be chewed, crushed, or split unless specifically instructed by a healthcare professional.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe pancreatitis, significant liver toxicity, and rare but severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for cardiac, hepatic, and pancreatic function.

Nilotinib should not be used by patients with a known hypersensitivity to the drug or any of its components, by pregnant or nursing women, and by individuals with uncontrolled cardiac disease, significant QT prolongation, or severe hepatic impairment. Clinicians must evaluate each patient’s medical history before initiating therapy.